Akoya Biosciences, Inc. (NASDAQ:AKYA) Shares Sold by HighTower Advisors LLC

HighTower Advisors LLC lessened its position in Akoya Biosciences, Inc. (NASDAQ:AKYA) by 25.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,200 shares of the company’s stock after selling 7,000 shares during the period. HighTower Advisors LLC’s holdings in Akoya Biosciences were worth $55,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of AKYA. GSA Capital Partners LLP grew its stake in Akoya Biosciences by 87.4% in the 3rd quarter. GSA Capital Partners LLP now owns 310,669 shares of the company’s stock worth $845,000 after acquiring an additional 144,903 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Akoya Biosciences by 16.2% during the second quarter. Bank of New York Mellon Corp now owns 67,468 shares of the company’s stock worth $158,000 after purchasing an additional 9,429 shares during the last quarter. Finally, Regal Investment Advisors LLC grew its position in shares of Akoya Biosciences by 64.3% in the second quarter. Regal Investment Advisors LLC now owns 18,760 shares of the company’s stock valued at $44,000 after purchasing an additional 7,340 shares during the period. Hedge funds and other institutional investors own 79.42% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. Piper Sandler reiterated an “overweight” rating and set a $3.00 target price (down from $4.00) on shares of Akoya Biosciences in a research report on Tuesday, November 19th. Canaccord Genuity Group cut their price objective on shares of Akoya Biosciences from $6.00 to $3.50 and set a “buy” rating on the stock in a report on Friday, November 15th. Finally, Craig Hallum downgraded shares of Akoya Biosciences from a “buy” rating to a “hold” rating and lowered their target price for the company from $7.00 to $5.00 in a report on Friday, November 15th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $5.43.

Akoya Biosciences Stock Performance

NASDAQ AKYA opened at $2.46 on Friday. The company has a debt-to-equity ratio of 5.62, a current ratio of 2.75 and a quick ratio of 1.85. Akoya Biosciences, Inc. has a 1-year low of $1.88 and a 1-year high of $6.31. The firm has a market capitalization of $121.92 million, a P/E ratio of -2.08 and a beta of 1.22. The business’s 50-day simple moving average is $2.57 and its 200-day simple moving average is $2.51.

Akoya Biosciences Profile

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.